Topics

FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)

13:57 EDT 14 Aug 2019 | HIT Consultants

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, ... Read More

Original Article: FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)

NEXT ARTICLE

More From BioPortfolio on "FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...